Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib plus carboplatin/paclitaxel versus standard chemotherapy in first-line advanced non-squamous NSCLC in smokers
2014-002565-30Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of veliparib, carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Overall survival in current smokers. Started Oct 2014; status: completed.
02
Drugs
veliparibcarboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2014-002565-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002565-30.